Cardiff Oncology announces interim Phase 2 CRDF-004 trial results for onvansertib
Cardiff Oncology released interim results from its randomized Phase 2 CRDF-004 trial evaluating onvansertib combined with standard chemotherapy and bevacizumab for first-line RAS-mutated metastatic colorectal cancer. The trial data may impact the company's clinical development pathway and commercial prospects for this oncology candidate.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day